<DOC>
	<DOCNO>NCT02965040</DOCNO>
	<brief_summary>For subject normal renal function severely impaired renal function , study evaluate pharmacokinetics roxadustat main metabolite plasma urine . For subject end stage renal disease ( ESRD ) continuous ambulatory peritoneal dialysis ( CAPD ) automate peritoneal dialysis ( APD ) , study evaluate pharmacokinetics roxadustat main metabolite plasma , urine dialysate . For subject ESRD hemodialysis ( HD ) hemodiafiltration ( HDF ) , study evaluate pharmacokinetics roxadustat main metabolite plasma , urine dialysate also effect dialysis pharmacokinetics roxadustat main metabolite .</brief_summary>
	<brief_title>A Phase 1 Study Roxadustat Subjects With Different Degrees Renal Function</brief_title>
	<detailed_description>This phase 1 , open-label study two site . There four different renal function group . For subject : Subjects allocate normal severely impaired renal function group base estimate glomerular filtration rate ( eGFR ) , calculate abbreviated modification diet renal disease ( MDRD ) equation . The eGFR base serum creatinine concentration assess screening day -2 . The eGFR obtain screen determine allocation . Subjects allocate ESRD group base dialysis requirement . Subjects normal severely impaired renal function , subject ESRD CAPD APD : Screening take place day -30 day -3 subject admit clinical unit day -2 . The treatment period last 8 day , subject receive single oral dose roxadustat morning day 1 Subjects complete treatment period day 6 , provide required assessment perform medical reason prolong follow-up . The study complete end-of-study visit ( ESV ) , take place 5 9 day last treatment period-defined assessment ( early withdrawal ) . Subjects ESRD HD HDF : Screening take place day -30 day -3 subject complete 2 treatment period 8 day ( period 1 ) 7 day ( period 2 ) order evaluate pharmacokinetics roxadustat single oral dose roxadustat day 1 period dialysis . Subjects complete treatment period 1 day 6 follow wash-out period minimally 1 week maximally 3 week . Subjects complete period 2 day 6 , provide required assessment perform medical reason prolong follow-up . The study complete end-of-study visit ( ESV ) , take place 5 9 day last treatment period-defined assessment ( early withdrawal ) . All subject : Safety assessment perform throughout study . An optional biobanking sample may take potential exploratory , retrospective , gene polymorphism analysis . Roxadustat plasma , urine , dialysate sample store potential exploratory metabolic profile exploratory biomarker analysis study .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion criterion subject : Subject body weight 45 160 kg , inclusive . For subject ESRD CAPD APD body weight record measure body weight minus abdominal dialysis fluid base last filling . For subject ESRD HD HDF postdialysis body weight record . Specific inclusion criterion subject normal renal function : Subject healthy male female subject age 40 75 year , inclusive . Subject must predose eGFR value base abbreviated MDRD method great equal 90 mL/min/1.73 m^2 . Specific inclusion criterion subject severely impaired renal function : Subject male female subject age 18 75 year , inclusive . Subject must predose eGFR value base abbreviated MDRD method [ screen ] &lt; 30 mL/min/1.73 m^2 dialysis . Specific inclusion criterion subject ESRD CAPD APD : Subject male female subject age 18 75 year , inclusive . Subject CAPD APD treatment mode dialysis least 4 month prior admission clinical unit . Specific inclusion criterion subject ESRD HD HDF : Subject male female subject age 18 75 year , inclusive . Subject HD HDF treatment mode dialysis least 4 month prior admission clinical unit dialysis session three time weekly . Specific inclusion criterion subject impair renal function include severly impaired renal function ESRD : If subject treat shortacting ESAs , subject agree discontinue treatment least 14 day prior admission . Exclusion criteria subject : Subject know suspected hypersensitivity Roxadustat component ( e.g. , lactose ) formulation use . Subject clinically significant history allergic condition ( include drug allergy anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior admission clinical unit . Subject clinically significant abnormality follow investigator 's review physical examination , electrocardiogram ( ECG ) , clinical study protocoldefined clinical laboratory test screen day 2 . Subject history smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission clinical unit . Subject history drink 21 unit ( male subject ) 14 unit ( female subject ) alcohol per week ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 % ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) within 3 month prior admission clinical unit . Subject use moderate strong inducer metabolism ( e.g. , barbiturate , rifampin ) regularly 1 month prior admission clinical unit . Subject must consume grapefruit ( grapefruitcontaining product , include juice ) Seville orange ( Seville orangecontaining product , include juice ) within 7 day prior admission clinical unit . Subject use drug abuse within 3 month prior admission clinical unit . Subject positive serology test hepatitis B surface antigen ( HBsAg ) , antihepatitis A virus ( immunoglobulin M [ IgM ] ) , antihepatitis C virus , hepatitis B core antibody antihuman immunodeficiency virus ( HIV ) type 1 2 [ screen ] . Subject participate clinical study treat investigational drug within 28 day ( 5 halflives whichever longer ) , prior screen . Subject condition make subject unsuitable clinical study participation . Subject vulnerable subject ( e.g. , subject kept detention ) . Specific exclusion criterion subject normal renal function : Subjects age great equal 40 &lt; 65 : Subject mean pulse &lt; 45 &gt; 90 bpm ; mean systolic blood pressure &lt; 90 mmHg &gt; 140 mmHg ; mean diastolic blood pressure &lt; 50 mmHg &gt; 90 mmHg day 2 . Vital sign measurement take triplicate subject rest supine position 5 minute ; pulse measure automatically . If mean pulse , systolic blood pressure diastolic blood pressure exceed limit , 1 additional triplicate take [ day 2 ] . Subjects age great equal 65 less equal 75 : Subject mean pulse &lt; 45 &gt; 90 bpm ; mean systolic blood pressure &lt; 90 mmHg &gt; 160 mmHg ; mean diastolic blood pressure &lt; 50 mmHg &gt; 100 mmHg day 2 . Vital sign measurement take triplicate subject rest supine position 5 minute ; pulse measure automatically . If mean pulse , systolic blood pressure diastolic blood pressure exceed limit , 1 additional triplicate take [ day 2 ] . Subject history evidence clinically significant cardiovascular , gastrointestinal , endocrine , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , psychiatric , dermatologic , renal and/or major disease malignancy . Subjects age great equal 40 &lt; 65 : Subject mean correct QT interval use Fridericia 's formula ( QTcF ) &gt; 430 m ( male ) &gt; 450 m ( female ) day 2 . If mean QTcF exceed limit , 1 additional triplicate Electrocardiogram ( ECG ) take ( day 2 ) . Subjects age great equal 65 less equal 75 : Subject mean QTcF &gt; 450 m ( male ) &gt; 470 m ( female ) day 2 . If mean QTcF exceed limit , 1 additional triplicate ECG take ( day 2 ) . Subject liver chemistry test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase [ ALP ] , gammaglutamyl transferase [ GGT ] total bilirubin [ TBL ] ) 1.5 time upper limit normal ( ULN ) day 2 . In case , assessment may repeat [ day 2 ] . Subject use prescribe nonprescribed drug ( include vitamin , calcium , magnesium iron supplement , natural herbal remedy , e.g. , St. John 's Wort ) within 2 week ( 5 halflives , whichever long ) prior admission clinical unit , except occasional use paracetamol ( 2 g per day ) oral contraceptive hormone replacement therapy . Specific exclusion criterion subject impair renal function ( include severely impaired renal function ESRD ) : Subject mean pulse &lt; 45 &gt; 90 bpm ; mean systolic blood pressure &lt; 90 mmHg &gt; 160 mmHg ; mean diastolic blood pressure &lt; 50 mmHg &gt; 100 mmHg day 2 . Vital sign measurement , take triplicate subject rest supine position 5 minute ; pulse measure automatically . If mean pulse , systolic blood pressure diastolic blood pressure exceed limit , 1 additional triplicate take [ day 2 ] . Subject history clinically significant illness ( renal disease condition related renal disease , stable diabetes stable hypertension ) , medical condition , laboratory abnormality within 3 month prior screen would preclude participation clinical study . Subject use immunosuppressant drug drug use treat malignancy ( include corticosteroid dos &gt; 10 mg prednisolone per day equivalent ) within 3 month prior admission clinical unit . Subject anticipated undergo surgery expect lead significant blood loss clinical study period anticipate coronary revascularization . Subject anticipated use follow prohibited medication treatment and/or followup study : Oral multivalent cationcontaining drug mineral supplement ( e.g. , iron , calcium , magnesium , aluminium ) , anionexchange resin ( e.g. , colestyramine ) , sucralfate magnesium aluminiumcontaining antacid , phosphate binder , ironchelating agent allow 24 hour 48 hour dose . Shortacting intravenous ( IV ) subcutaneous ( SC ) Erythropoiesis stimulate agent ( ESA ) allow within 2 week prior admission clinical unit ESV . Dapsone dose amount anticipate chronic use paracetamol &gt; 2 g/day nonsteroidal antiinflammatory drug ( NSAIDs ) , except low dose aspirin/acetylsalicylic acid , allow admission clinical unit ESV . Subject stable dose concomitant medication treat concurrent chronic condition least 2 week ( 5 halflives drug , whichever long ) prior admission clinical unit ( minor dose change allow agreement Sponsor ) . Doses statin exceed cap maximum daily dos admission clinical unit . Rosuvastatin use allow . Subject require , likely require , new concomitant medication time screen ESV . Subject use nonessential prescribed nonprescribed drug ( include vitamin , natural herbalremedies ( e.g. , St. John 's Wort ) within 2 week ( 5 halflives , whichever long ) prior admission clinical unit . Subject mean QTcF &gt; 450 m ( male ) &gt; 470 m ( female ) day 2 . If mean QTcF exceed limit , 1 additional triplicate ECG take ( day 2 ) . Subject renal disease secondary malignancy . Subject fluctuate rapidly deteriorate renal function within 4 week prior admission clinical unit , indicate strongly vary worsen clinical and/or laboratory sign renal impairment within screen period . Subject serum uric acid &gt; 2 x ULN . In case assessment may repeat [ day 2 ] . Subject liver chemistry test ( AST , ALT TBL ) range indicate . In case assessment may repeat [ day 2 ] . ALT AST &gt; 3 x ULN TBL &gt; 1.5 x ULN Subject prior organ transplant ( explanted ) subject schedule organ transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ASP1517</keyword>
	<keyword>Normal renal function</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Roxadustat</keyword>
	<keyword>Metabolites</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Impaired renal function</keyword>
</DOC>